H
Hans-Peter Vornlocher
Researcher at Hoffmann-La Roche
Publications - 9
Citations - 1267
Hans-Peter Vornlocher is an academic researcher from Hoffmann-La Roche. The author has contributed to research in topics: Gene & Small interfering RNA. The author has an hindex of 6, co-authored 9 publications receiving 1195 citations. Previous affiliations of Hans-Peter Vornlocher include Alnylam Pharmaceuticals.
Papers
More filters
Journal ArticleDOI
Therapeutic RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primates
Maria Frank-Kamenetsky,Aldo Grefhorst,Norma N. Anderson,Timothy Racie,Birgit Bramlage,Akin Akinc,David Butler,Klaus Charisse,Robert Dorkin,Yupeng Fan,Christina Gamba-Vitalo,Philipp Hadwiger,Muthusamy Jayaraman,Matthias John,K. Narayanannair Jayaprakash,Martin Maier,Lubomir Nechev,Kallanthottathil G. Rajeev,Timothy Read,Ingo Röhl,Jürgen Soutschek,Pamela Tan,Jamie Wong,Gang Wang,Tracy Zimmermann,Antonin de Fougerolles,Hans-Peter Vornlocher,Robert Langer,Daniel G. Anderson,Muthiah Manoharan,Victor Koteliansky,Jay D. Horton,Kevin Fitzgerald +32 more
TL;DR: PCSK9 targeting with RNAi therapeutics as an approach to specifically lower LDLc is validated, paving the way for the development of PCSK9-lowering agents as a future strategy for treatment of hypercholesterolemia.
Journal ArticleDOI
Hepatocyte-targeted RNAi Therapeutics for the Treatment of Chronic Hepatitis B Virus Infection
Christine I. Wooddell,David B. Rozema,Markus Hossbach,Matthias John,Holly Hamilton,Qili Chu,Julia Hegge,Jason Klein,Darren H. Wakefield,Claudia E. Oropeza,Jochen Deckert,Ingo Roehl,Kerstin Jahn-Hofmann,Philipp Hadwiger,Hans-Peter Vornlocher,Alan McLachlan,David L. Lewis +16 more
TL;DR: It is shown that a single coinjection of NAG-MLP with potent chol-siRNAs targeting conserved HBV sequences resulted in multilog repression of viral RNA, proteins, and viral DNA with long duration of effect.
Journal ArticleDOI
Effective RNAi-mediated gene silencing without interruption of the endogenous microRNA pathway
Matthias John,Rainer Constien,Akin Akinc,Michael S. Goldberg,Young Ah Moon,Martina Spranger,Philipp Hadwiger,Jürgen Soutschek,Hans-Peter Vornlocher,Muthiah Manoharan,Markus Stoffel,Robert Langer,Daniel G. Anderson,Jay D. Horton,Victor Koteliansky,David Bumcrot +15 more
TL;DR: It is shown that effective target-gene silencing in the mouse and hamster liver can be achieved by systemic administration of synthetic siRNA without any demonstrable effect on miRNA levels or activity.
Patent
Compositions and Methods for Inhibiting Expression of Eg5 Gene
TL;DR: In this article, a double-stranded ribonucleic acid (dsRNA) was used for inhibiting the expression of the Eg5 gene (Eg5 gene), comprising an antisense strand having a nucleotide sequence which is less than 30 nucleotides in length.
Journal ArticleDOI
Hepatitis B virus genome replication triggers toll-like receptor 3-dependent interferon responses in the absence of hepatitis B surface antigen
CI Real,Mengji Lu,Jia Liu,Jia Liu,Xuan Huang,Martin Trippler,Markus Hossbach,Jochen Deckert,Kerstin Jahn-Hofmann,L Ickenstein,L Ickenstein,Matthias John,Kathrin Gibbert,Ulf Dittmer,Hans-Peter Vornlocher,Reinhold Schirmbeck,Guido Gerken,Joerg F. Schlaak,Ruth Broering +18 more
TL;DR: It is hypothesized that HBsAg is a major HBV-mediated evasion mechanism controlling endogenous antiviral responses in the liver, and Eradication ofHBsAg as a therapeutic goal might facilitate the induction of endogenous antiv viral immune responses in patients chronically infected with HBV.